Application
Tocainide hydrochloride may be used in cell signaling studies.
Biochem/physiol Actions
Tocainide hydrochloride is a primary amine analog of lidocaine (lignocaine), used for the treatment of tinnitus. It blocks the sodium channels in the pain-producing foci in the nerve membranes and renders an analgesic effect in trigeminal neuralgia.
Tocainide hydrochloride is a sodium channel blocker; Class IB antiarrhythmic.
Features and Benefits
This compound was developed by AstraZeneca. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Tocainide is voltage-dependent and use-dependent sodium channel blocker (class IB type antiarrhythmic); Ki = 115 μM in blockade of inactivated-state sodium channels; IC50 = 985μM in blockade of Na+ currents at a holding potential (HP) of -140 mV; IC50 = 254 μM in blockade of Na+ currents at HP -70 mV; IC50 = 523 μM in blockade of Na+ currents at tonic block (-100 mV); IC50 = 248 μM for use-dependent block at 10 Hz.
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | solid |
| storage condition | desiccated,under inert gas |
| color | white |
| solubility | DMSO: >20 mg/mL,H2O: ≥5 mg/mL |
| originator | AstraZeneca |
| storage temp. | 2-8°C |
| SMILES string | Cl[H].CC(N)C(=O)Nc1c(C)cccc1C |
| InChI | 1S/C11H16N2O.ClH/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12;/h4-6,9H,12H2,1-3H3,(H,13,14);1H |
| InChI key | AMZACPWEJDQXGW-UHFFFAOYSA-N |
| Gene Information | human ... SCN10A(6336), SCN11A(11280), SCN1A(6323), SCN2A(6326), SCN3A(6328), SCN4A(6329), SCN5A(6331), SCN7A(6332), SCN8A(6334), SCN9A(6335) |
